A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive, according to news from the U.S. Food and Drug Administration. RSV is a highly contagious, common respiratory ...

The halt was triggered by an “imbalance,” the FDA said, in cases of severe lower respiratory tract infections (LRTIs) in children in a phase 1 trial of two Moderna RSV vaccines. One of the ...

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Safety and immunogenicity data from ongoing studies in adults and RSV-seropositive children aged 12 months through 59 months ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

The trial, which tested two Moderna RSV vaccines, mRNA-1365 and mRNA-1345, found that infants who received a 15-microgram dose of either vaccine had a higher incidence of severe lower respiratory ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...

The document notes that a phase 1 trial of two experimental Moderna RSV vaccines in infants aged five to eight months was paused in July. The pause came after five cases of severe to very severe ...

Infants are among the most vulnerable when it comes to RSV—but there's still no vaccination for them. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of ...

Infants are among the most vulnerable when it comes to RSV—but there's still no vaccination for them. A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive ...